Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

#2916

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Aim(s): The aim of this study was to evaluate the lesional asphericity (ASP) in pre-therapeutic somatostatin receptor (SSR) imaging as the first diagnostic predictive marker for PFS.

Materials and methods: A retrospective bicentric cohort study in 30 patients (m=17, w=13, median age, 59 [38-75] years) with pre-therapeutic [111In-DTPA0]octreotide scintigraphy (Octreoscan®). The functional volumes of up to 3 leading lesions per patient (n=74) were assessed by semiautomatic, background-adapted segmentation (ROVER, version 2.1.20) and the heterogeneity of lesional SSR expression, the asphericity (ASP), was calculated. Kaplan-Meier (KM) analysis and log-rank test as well as univariate Cox regression with respect to progression-free survival (PFS) were performed for the maximum ASP measured per patient.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,